Shyh-Han Tan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1557276/publications.pdf

Version: 2024-02-01

45 papers	2,733 citations	257357 24 h-index	276775 41 g-index
46 all docs	46 docs citations	46 times ranked	3187 citing authors

#	Article	IF	Citations
1	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. Scientific Reports, 2022, 12, 5404.	1.6	10
2	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. Nature Communications, 2022, 13, 1361.	5.8	8
3	Abstract 3805: Immunologic transcript and cell type evaluation of prostate tumors from a military cohort of African American and Caucasian American patients. Cancer Research, 2022, 82, 3805-3805.	0.4	0
4	Abstract 2220: Immunohistochemical detection of prostate cancer heterogeneity by using ETS and PTEN monoclonal antibodies. Cancer Research, 2022, 82, 2220-2220.	0.4	0
5	Prognostic features of Annexin A2 expression in prostate cancer. Pathology, 2021, 53, 205-213.	0.3	15
6	Abstract 2565: Detection of ETV1 expression in human prostate tissue specimens using a novel and highly specific rabbit monoclonal antibody. , 2021, , .		0
7	Abstract 2074: Germline mutation landscape of all DNA repair genes in African American prostate cancer patients. , 2021, , .		0
8	Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifiesERGas the strongest independent predictor of recurrence. Oncotarget, 2019, 10, 6466-6483.	0.8	10
9	Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. Cancer Research, 2018, 78, 3659-3671.	0.4	44
10	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. International Journal of Molecular Sciences, 2018, 19, 1255.	1.8	50
11	Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells. Molecular Cancer Research, 2017, 15, 1308-1317.	1.5	31
12	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. Scientific Reports, 2017, 7, 1109.	1.6	17
13	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes and Cancer, 2017, 7, 394-413.	0.6	14
14	Prostate cancer marker panel with single cell sensitivity in urine. Prostate, 2015, 75, 969-975.	1.2	26
15	A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine, 2015, 2, 1957-1964.	2.7	61
16	ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. Molecular and Clinical Oncology, 2015, 3, 23-30.	0.4	8
17	Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 713-726.	1.9	16
18	ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer. Molecular Cancer Research, 2015, 13, 368-379.	1.5	12

#	Article	IF	Citations
19	Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. Journal of Translational Medicine, 2015, 13, 54.	1.8	23
20	ERG Monoclonal Antibody in the Diagnosis and Biological Stratification of Prostate Cancer: Delineation of Minimal Epitope, Critical Residues for Binding, and Molecular Basis of Specificity. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2014, 33, 201-208.	0.8	7
21	ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2014, 17, 126-131.	2.0	17
22	Evaluation of ERG responsive proteome in prostate cancer. Prostate, 2014, 74, 70-89.	1.2	21
23	Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer, 2014, 14, 16.	1.1	25
24	Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes and Cancer, 2014, 5, 273-284.	0.6	8
25	ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancerâ€"a comparative study of two monoclonal antibodies. Prostate Cancer and Prostatic Diseases, 2012, 15, 165-169.	2.0	79
26	ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma. American Journal of Surgical Pathology, 2011, 35, 432-441.	2.1	338
27	ERGoncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biology and Therapy, 2011, 11, 410-417.	1.5	30
28	Highlights from the prostate cancer genome report. Asian Journal of Andrology, 2011, 13, 659-660.	0.8	0
29	ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer and Prostatic Diseases, 2010, 13, 228-237.	2.0	227
30	N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells. International Journal of Biochemistry and Cell Biology, 2010, 42, 2037-2046.	1.2	22
31	Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody. Journal of Cancer, 2010, 1, 197-208.	1.2	44
32	TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene, 2008, 27, 5348-5353.	2.6	218
33	Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocrine-Related Cancer, 2008, 15, 367-390.	1.6	95
34	Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells. Cancer Research, 2008, 68, 236-248.	0.4	96
35	Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor. Clinical Cancer Research, 2008, 14, 6062-6072.	3.2	32
36	SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. Journal of Cell Biology, 2006, 174, 939-949.	2.3	131

#	Article	IF	Citations
37	A Transcriptional Initiator Overlaps with a Conserved YY1 Binding Site in the Long Control Region of Human Papillomavirus Type 16. Virology, 2003, 305, 486-501.	1.1	19
38	SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles. Journal of Cell Biology, 2002, 156, 595-602.	2.3	259
39	Expression and regulation of the mammalian SUMOâ€1 E1 enzyme. FASEB Journal, 2001, 15, 1825-1827.	0.2	46
40	Nuclear Matrix Attachment Regions of Human Papillomavirus Type 16 Repress or Activate the E6 Promoter, Depending on the Physical State of the Viral DNA. Journal of Virology, 2000, 74, 2489-2501.	1.5	68
41	Nuclear Matrix Attachment Regions of Human Papillomavirus Type 16 Point toward Conservation of These Genomic Elements in All Genital Papillomaviruses. Journal of Virology, 1998, 72, 3610-3622.	1.5	39
42	YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity. Journal of Virology, 1996, 70, 6529-6539.	1.5	123
43	Efficient and Rapid Affinity Purification of Proteins Using Recombinant Fusion Proteases. Nature Biotechnology, 1994, 12, 601-605.	9.4	133
44	The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. Journal of Virology, 1994, 68, 6411-6420.	1.5	182
45	During negative regulation of the human papillomavirus-16E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. Nucleic Acids Research, 1992, 20, 251-256.	6.5	128